New Clinical Data Highlights Onera Health’s Patch-Based Home Polysomnography Solution at SLEEP 2025
4.6.2025 15:00:00 EEST | Business Wire | Press release
Onera Health, a leader in transforming remote sleep diagnostics and monitoring, has today announced that its patient-applied patch-based home Polysomnography Solution will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2025 conference. The MedTech company will showcase this innovative solution at booth #1145 during the largest annual conference, which brings together leading experts and innovators in the field of sleep medicine. Furthermore, Onera Health will host a symposium on "Advancing Access to PSG" on Monday, June 9.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250604390799/en/
A female patient is sleeping while undergoing a sleep study with Onera Health's home Polysomnography solution.
The 39th annual meeting of the Associated Professional Sleep Societies (APSS) will present the latest clinical data and insights that promise to reshape the landscape of sleep medicine. This year's conference will take place from June 8 to 11, 2025, in Seattle, Washington.
“We are excited to see our Patch-based Type II Polysomnography System highlighted in four different presentations and to be an integral part of the evolving field of sleep medicine by advancing access to the gold standard of PSG sleep testing,” states Ruben de Francisco, Founder and CEO of Onera Health.
The clinical utility of the Onera home PSG system will be presented in four poster presentations. Details of the presentations are as follows:
Title: Assessment of Disease Burden in PAP-Intolerant OSA Patients Using Home Polysomnography: A Pilot Study
Authors: Heiser C et al.
Poster Board Number: #219
Poster Presentation Date and Time: June 9, 2025, 10:00 - 11:45 am
Abstract ID: 661
Title: Signal Quality and Recording Characteristics of Patient-Applied Home Polysomnography: A Real-World Analysis Across US and European Settings
Authors: Dimitrov T et al.
Poster Board Number: #543
Poster Presentation Date and Time: June 10, 2025, 11:00 - 11:45 am
Abstract ID: 1666
Title: Validation of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #319
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 677
Title: Patient Perception of a Novel Patch-Based Type II Polysomnography System
Authors: Schneider H et al.
Poster Board Number: #320
Poster Presentation Date and Time: June 11, 2025, 10:00 - 11:45 am
Abstract ID: 678
Additional presentations by experts from leading institutions will feature validation results, insights from real-world implementation, and the clinical implications of home PSG testing during a symposium titled "Expanding Access, Enhancing Outcomes: The Future of Sleep Diagnostics with Home Polysomnography," which will be hosted by Onera Health on June 9.
“Home polysomnography addresses significant challenges, including the shortage of in-laboratory beds, technicians, and sleep physicians. This shortage has led to escalating costs and an increasing unmet clinical demand, with many patients suffering from sleep disorders remaining undiagnosed. This symposium aims to provide valuable insights into how hPSG can enhance patient care pathways and is already beginning to reshape the landscape of sleep healthcare by broadening access to gold standard PSG testing. I am confident that it will foster engaging discussions with esteemed panelists regarding the emerging opportunities for remote sleep diagnostics and care,” explains Ruben de Francisco.
Attendees can anticipate the following presentations:
- David P. White, MD, part-time Professor of Medicine at Harvard Medical School – "The Perfect Storm: Why Sleep Medicine Needs to Transform Now"
- Thomas Penzel, PhD, Charité University Hospital Berlin – "Home Polysomnography Comes of Age: Validation Study Results"
- Anupamjeet Kaur Sekhon, MD, Kaiser Permanente Fontana Medical Center– "From Lab to Home: Implementing Home Sleep Testing at Scale"
About Onera Health
Onera Health is a leader in transforming sleep medicine and remote monitoring. Their breakthrough diagnostic solutions and services are poised to help millions of people struggling with sleep-related ailments while also impacting other medical fields by monitoring various chronic conditions, ultimately improving the health and quality of life of patients worldwide. The company’s innovative solutions provide comprehensive sleep test data to physicians in a variety of clinical and non-clinical environments to optimize patient care and reduce healthcare costs. Onera has offices in the Netherlands and the United States. For further information, please visit onerahealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250604390799/en/
Contacts
Swea Ann Hagenhoff
E: media@onerahealth.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom